AIMP2 and hematopoietic and lymphoid cell neoplasm: Collectively, our work provides the development of tools for quantitative assessment of alternatively spliced variants and clinical implications of AIMP2-DX2, as a potential biomarker and therapeutic target in hematologic cancer.